1. Introduction {#s0005}
===============

N~2~O, used for more than 150 years, acts supraspinally to induce analgesia by activation of opioidergic neurons in the periaqueductal gray matter and noradrenergic neurons in the *locus coeruleus*, A5 and A7 areas of the brainstem. N~2~O was considered to be completely benign until 1956 \[[@bb0005]\] when several tetanus patients were reported with acute bone marrow aplasia after prolonged N~2~O anesthesia \[[@bb0010]\]. Later, neurological symptoms such as numbness, sensitive deficiency, hyporeactive tendon reflexes were reported to be attributed to N~2~O abuse \[[@bb0015]\]. Since then, several studies described neuropathy following prolonged exposure to nitrous oxide.

N~2~O neurological toxicity is related to its inhibition of vitamin B12 metabolism. In the sixties, an interaction between N~2~O and the cobalt atome of the cobalamin (vitamin B12) was demonstrated \[[@bb0020]\]. Precisely, N~2~O oxidizes the cob\[*I*\]alamin (Co^+^) into cob\[*II*\]alamin (Co^2+^), which affects its binding to the vitamin B12-dependent enzymes namely methionine synthase (EC [2.1.1.13](https://www.brenda-enzymes.org/enzyme.php?ecno=2.1.1.13){#ir0005}) and methylmalonyl-CoA mutase (EC 5.4.99.2) \[[@bb0025]\]. Consequently, homocysteine and methylmalonic acid (MMA) accumulate while methionine is depleted ([Fig. 1](#f0005){ref-type="fig"}). The functional deficit of vitamin B12 leads to myelinopathy such as subacute neurodegeneration of the spinal cord but also megaloblastic bone marrow failure and abnormalities in other rapidly regenerating tissues such as gastrointestinal tract and skin \[[@bb0030]\]. Homocysteine accumulation itself can induce thrombotic events \[[@bb0035],[@bb0040]\].Fig. 1Vitamin B12 metabolism schematic view.MTHF-R: methyltetrahydrofolate reductase; THF: tetrahydrofolate.Fig. 1

N~2~O is used in the first line of treatment of vaso-occlusive crisis of children with sickle cell disease \[[@bb0045]\]. Thus, these children are highly exposed to N~2~O, leading to a higher risk of potential side effects. Moreover, sickle cell disease is responsible for chronic hemolysis with subsequent risk of vitamin B12 overconsumption. Children with sickle cell disease are also at risk of thrombotic vasculopathy, which can be aggravated by hyperhomocysteinemia that promotes thrombo-embolic events \[[@bb0050]\]. Only few patients with sickle cell disease were reported with functional vitamin B12 deficiency revealed by neurological signs as a consequence of N2O over exposure \[[@bb0055], [@bb0060], [@bb0065]\].

We report herein a 13 year old girl with sickle cell disease with neurological and biochemical signs of severe functional vitamin B12 deficiency due to prolonged and recurrent exposure to N~2~O and compare this case with other similar published cases. This single case of severe N~2~O toxicity was an incentive to prospectively investigate functional vitamin B12 deficiency in patients affected by sickle cell disease. We measured plasma concentrations of vitamin B12, total homocysteine, methionine and MMA in 39 patients with sickle cell disease exposed to N~2~O between 2015 and 2016.

2. Materials and methods {#s0010}
========================

2.1. Study design {#s0015}
-----------------

We conducted a monocentric observational prospective study in Robert-Debré University Hospital Department of Paediatrics between November 2015 and November 2016 (agreement N° 2015-02-08-SC/ ethical research committee "Ile-De-France II" / CNIL N°1,827,740).

We included all children between one month and 17 years of age with sickle cell disease (SS, SC or Sβ0), hospitalized for a vaso-occlusive crisis, with a need for a blood sample and a non-opposition from the legal guardians. We excluded all children whose haemoglobin level was below 5 g/dl, who had been transfused in the last 3 months, who were in a transfusion program, who did not need a blood test or who already had 2 blood samples taken for the study. For each patient, duration of exposure to N~2~O, the total number of vaso-occlusive crisis and the number of emergency room visit since diagnosis were collected. All data were recorded anonymously from the medical records*.*

2.2. Samples {#s0020}
------------

Blood was drawn at the end of each hospitalization. Blood with heparin added as anticoagulant was used for analysis of plasma of total homocysteine (tHCy), methionine (Meth), MMA and vitamin B12. Blood without anticoagulant was used for serum folate measurement.

2.3. Laboratory measurements {#s0025}
----------------------------

Plasma MMA, tHCy) and Meth were analyzed by ESI-LC-MS/MS method adapted from Imbard et al. \[[@bb0070]\] (Acquity-I Class UPLC- XevoTQD, Waters).

Plasma Vitamin B12 and serum folates were measured by competitive immunoenzymatic methods (Automate Access Beckman Coulter).

2.4. Statistical analyses {#s0030}
-------------------------

Descriptive statistics were used to summarize baseline demographics and laboratory parameters. We reported the mean ± standard deviation and \[min;max\] of continuous data.

3. Case report {#s0035}
==============

This girl was diagnosed with homozygous S/S sickle cell disease at 4 years of age in Gabo. At age 13, she exhibited an acute chest syndrome, complicated by a disseminated osteomyelitis. She was transferred to France where she received important amounts of N~2~O due to high pain (minimal of 1.5 h daily during 7 months). She further exhibited complete loss of any movements in the lower limbs with absence of deep tendon reflexes compatible with peripheral neuropathy. No electrophysiological studies were possible due to the severity of the clinical condition. However, due to the possibility of overt N~2~O exposure, serum vitamin B12, plasma tHCy, Meth and MMA were measured (day 0). Plasma tHcCy and urinary MMA were highly elevated (\> 10 fold) while plasma methionine was decreased ([Table 1](#t0005){ref-type="table"}). Vitamin B12 and folate were in the normal range. These results suggested a functional vitamin B12 deficiency. N~2~O was initially maintained due to the high pain intensity and oral vitamin B12 was added during 5 days. At day 32, N~2~O was discontinued allowing rapid normalization of metabolic parameters ([Table 1](#t0005){ref-type="table"}). Two months later, she received intramuscular vitamin B12 injection during 2 days followed by 5 days of oral vitamin B12 due to mild elevation of tHCy. This allowed normalization of homocysteine concentration while pain and signs of neurological toxicity disappeared after a few weeks ([Table 1](#t0005){ref-type="table"}).Table 1Laboratory parameters and various treatments used.Table 1Timeday 0day +32day +68day +80day +148day +183day +214Treatments:Nitrous oxideYesYesNoneNoneNoneNoneNoneVitamin B12None1 mg/d PO (5 days)None1 mg/d IM (2 days)\
1 mg/d PO (5 days)None1 mg/d PO (7 days)NonetHcy (5--9 μM)**1556623**676Meth (15--27 μM)**11111015181918**Plasma MMA (\< 0.4 μM)2.90.5\<0.4Urine MMA (\<20 μmol/mmol creatinine)**9004138**1316Plasma vitamin B12 (140--780 pM)226146685153332Hb (11.3--14.4 g/dL)12.6**9.48.710.010.610.4**Mean corpuscular volume (75--88 fL)**90.6**84.686.586.787.580.0[^3][^4]

4. Results of the prospective study {#s0040}
===================================

4.1. Population description {#s0045}
---------------------------

Sixty-one patients met the inclusion criteria. All patients received N~2~O at each hospitalization for vaso-occlusive crisis with at 6 to 12 L per minute with a maximum of 1 h but it was not possible to precisely quantify the duration of administration. We excluded 22 patients who had received red blood cell transfusion in the last 3 months. In total, 39 patients were analyzed (21 girls and 18 boys). The mean age of our population was 10.6 ± 5.3 years \[1.4;17.8\]. Thirty-two patients had homozygous sickle cell anemia (HbSS) while 7 had one HbS allele and one HbC allele (HbSC). Twenty-three patients were treated by hydroxycarbamide. Among the 39 patients, 7 had a splenectomy and 4 had a cerebral vasculopathy. Patients exhibited 3.1 ± 3.0 \[0;12\] vaso-occlusive crisis per year during the previous year; and 1.9 ± 1.2 \[0;5\] during the 3 months period prior to inclusion.

4.2. Laboratory parameters {#s0050}
--------------------------

Demographic data and laboratory parameters are detailed in [Table 2](#t0010){ref-type="table"}.Table 2Laboratory results of the study.Table 2PatientAge at inclusion (years)SexBasal Hb rateBMINumber of vaso-occlusive crises in 12 monthsNumber of vaso-occlusive crises in 3 monthsVitamin B12 (140--780 pM)Methionine (15--27 μM)tHcy (5--9 μM)AMM (\< 0.4 μM)Serum folates (\> 18 μg/L)RBC folates (390--1900 μg/L)17.8Male911593**14**3NC98232525.4Female7.500**9**6\< 0.432.0Male8.516.4822581**10**30.197.7361442.0Male8.516.482281150.1513.1Male716.23532352360.1447.5133461.9Female900229\< 0.495.11234717.3Male920.5542**90**19**11**\< 0.4434.71732813.0Male8**11.56**31348184\< 0.43572037914.8Female1021.2811**136**207\< 0.4108.2Female8.514.0124303166\< 0.4918.6\>1974119.5Female8.518.6661243**11**4\< 0.419725091213.7Female720.1233188207**0.44**46425041313.7Female720.1234175\< 0.4142.6Male915.0711224\< 0.41517.5Male7.5**16.87**122158**0.54**1610.1Male8.516.8431147228\< 0.41250\>754176.3Female915.2001276\< 0.41817.1Female9.522.4341171**1310**\< 0.421.12674193.1Female916.9112419194\< 0.4164.3\>41102011.9Male16.2321228\< 0.42115.8Male8**16.18**12226723**11**\< 0.42210.2Male8.5**14.48**32**121**226\< 0.42312.8Female7.515.1611239\< 0.4241.7Female8.511294\< 0.4251.4Female8.516.0211293\< 0.42614.4Female825.1082185\< 0.4274.3Male10.614.32323311630.353.43900288.4Female8.514.0135511216\< 0.448.227602917.4Male920.5553**110**257\< 0.41408.5\> 4403012.2Female8.517.2711222165\< 0.442.13112.6Female716.1213270229\< 0.4\>54.83217.8Male7.5**17.58**31140165\<0.450.8\>45413313.3Female7.518.5524364206\<0.415003412.8Female19.6364**14**7\<0.43511.7Male919.5231**24**NCNC\<0.43616.6Male1021.879230**19**\< 0.43712.8Female917.5812254287**0.85**3815.6Male8**16.22**2129817**13**\<0.4142.223153916.5Female9.420.2501495[^5]

Mean vitamin B12 concentration was in the normal range, 295 ± 183 pM. Five patients (13%) had a decreased vitamin B12 concentration.

Mean methionine concentration was in the normal range, 19.6 ± 5.3 μM. Six patients (15%) had a mild decreased methionine concentration.

Mean tHcy concentration was in the normal range (\<10 μM). Five patients (13%) had a slight increase of the tHcy between 10 and 19 μM.

Mean MMA plasma concentration was in the normal range (\<0.4 μM). Two patients had a slight increase of the plasma MMA concentration and one patient had an MMA increase at 2.1 fold of normal values.

5. Discussion {#s0055}
=============

We described the case of a young girl with S/S sickle cell disease who presented a peripheral neuropathy due to a functional vitamin B12 deficiency (i.e. with normal serum vitamin B12) ascribable to high N~2~O exposure. This led us to systematically investigate B12 vitamin metabolism in patients with sickle cell disease and hospitalized for a vaso-occlusive crisis receiving N~2~O. Our study revealed that almost half of the patients exhibited biological hallmarks of B12 vitamin metabolism but without neurological, hematological, or gastrointestinal symptoms suggestive of functional vitamin B12 deficiency.

However, our study has several limitations. Precise quantification of N~2~O dose was not possible due to the mode of administration (on demand). Moreover, the number of patients included was limited.

Overall, including our case report, seven patients affected with sickle cell disease and presenting with a functional vitamin B12 deficiency due to over exposure to N~2~O are reported in the literature. Ogundipe et al. \[[@bb0065]\] described in 1999 three adult patients with peripheral neuropathy and decreased walking ability. In 2013, Chaugny et al. described a sensorimotor polyneuropathy in a 20 years old patient affected by sickle cell disease \[[@bb0055]\]. Of note, similar to our case, highly elevated tHCy levels were also reported in this patient who exhibited a pulmonary embolism. Recently, Neveu et al. described two patients, one with peripheral while the other was asymptomatic despite a dramatic increase of homocysteine. All patients improved after N~2~O withdrawal and vitamin B12 supplementation \[[@bb0060]\].

All these reports led us to prospectively investigate functional vitamin B12 deficiency in children with sickle cell disease during vaso-occlusive crisis in our hospital. In contrast with our first observation, none of the 39 sickle cell other patients developed neurological symptoms in relation with N~2~O administration. Regardless, 49% had mild biochemical abnormalities i.e. either low vitamin B12, elevation of plasma tHCy or MMA, or decrease of Meth. These values remained very moderately abnormal and were not associated with symptoms that could be directly associated with vitamin B12 deficiency. Our data show that reasonable use of N~2~O in a hospital setting in sickle cell disease patients do not severely impact vitamin B12 metabolism. In line with our results, in 2016, the French medicine agency ANSM (Agence Nationale de Sécurité du Médicament) reminded to the Heath care professionals the duration of the administration of N~2~O should not exceed one hour a day during 15 consecutive days \[[@bb0075]\].

Besides sickle cell disease patients and N~2~O overexposure, a few case reports have described N~2~O toxicity in the rare situations of acquired or inherited vitamin B12 metabolism defects, without overexposure to N~2~O. Selzer et al. \[[@bb0080]\] described a 3 months old child with neurologic deterioration including severe hypotonia, absence of deep tendon reflexes, seizures and apnea leading to death. He had received 25 days prior to death twice N~2~O (one for a biopsy of a mass of the left leg which revealed an infantile fibrosarcoma and the second for the ablation of the tumor). Further investigations disclosed normal serum vitamin B12 but decreased Meth and increased tHCy. Post mortem investigations revealed 5,10-Methylenetetrahydrofolate reductase deficiency (MTHFR) deficiency. Felmet et al. \[[@bb0085]\] described in 2000, an eight months old patient who presented progressive coma associated with profound hypotonia and athetoid movements, six days after an anesthesia with N~2~O. He also presented a recent decline in growth velocity and mild developmental delay due to a profound vitamin B12 deprivation from maternal origin. He partially improves after vitamin B12 supplementation. Mc Neely et al. \[[@bb0090]\] described a six months old child who presented a neurologic degradation 3 weeks after receiving N~2~O anesthesia for a craniostenosis. Laboratory parameters revealed profound vitamin B12 deficiency partially due to maternal deficiency. The patient partially improved after intra muscular vitamin B12 administration. Those three cases emphasize that N~2~O even without overexposure could be responsible for an acute neurological degradation when primary or secondary vitamin B12 metabolism dysfunction preexists.

Many studies have also described N~2~O exposure in the context of recreational use \[[@bb0015],[@bb0095], [@bb0100], [@bb0105], [@bb0110], [@bb0115], [@bb0120], [@bb0125], [@bb0130], [@bb0135]\]. The picture is often a sensorimotor neuropathy and/or a medullary injury sometimes up to a combined sclerosis of spinal cord. Laboratory parameters found a vitamin B12 concentration normal or variably decreased, associated with signs of functional B12 vitamin deficiency (high tHCy, low Meth and MMA accumulation) in the range of those observed in our study.

To conclude, our data highlight the potential deleterious impact of N~2~O overexposure on vitamin B12 metabolism. However, regular but not excessive use of N~2~O in sickle cell disease patients can induce minor abnormalities in vitamin B12 metabolism though without obvious clinical signs and therefore is to be regarded as safe. Nevertheless, N~2~O administration should indeed be carefully monitored and quantified as any drug especially because unsuspected circumstances such as asymptomatic vitamin B12 deficiency can trigger severe neurological degradation. Last, functional B12 deficiency should be investigated by measuring metabolic parameters (vitamin B12, tHcy, Meth and MMA) prior to N~2~O administration in at-risk patients or in any patient with neurological symptoms or excessive nitrous oxide consumption.
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